Lupin receives tentative approval from USFDA for Valbenazine capsules
Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).
Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).
The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide
The patent was granted for creating a green catalyst for one of the world's most significant chemical reactions
Obeticholic Acid Tablets (RLD Ocaliva) had estimated annual sales of US $255 million in the US (IQVIA MAT December 2022).
PM emphasises the need to enhance lab surveillance & testing of all Severe Acute Respiratory Illness (SARI) cases & ramp up genome sequencing
Essex enriches and complements Emmes’ services
Women of all ages will get round-the-clock access to comprehensive treatment
Integration of modern and traditional medicine to facilitate the illness to wellness journey
This initiative encapsulates the essence of OPPI’s commitment towards enabling a healthier India
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
Subscribe To Our Newsletter & Stay Updated